← Oncology Approval Tracker

FDA DECISION ·

Pemazyre

pemigatinib · Incyte

Accelerated approvalNew therapyCholangiocarcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma and an FGFR2 fusion or other rearrangement identified by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

Created a targeted option for patients with specific FGFR2 alterations after prior treatment.

What research teams should watch

Arrange fusion-capable testing and build phosphate and eye monitoring into follow-up.

PRIMARY RECORDS

Sources